Towards early inclusion of children in tuberculosis drugs trials: A consensus statement

The Lancet Infectious Diseases

Volumn 15, Issue 6, 2015, Pages 711-720

  Nachman, Sharon ^a   Ahmed, Amina ^b   Amanullah, Farhana ^c   Becerra, Mercedes C ^d   Botgros, Radu ^e   Brigden, Grania ^f   Browning, Renee ^g   Gardiner, Elizabeth ^h   Hafner, Richard ^g   Hesseling, Anneke ⁱ   How, Cleotilde ^j   Jean Philippe, Patrick ^g   Lessem, Erica ^k   Makhene, Mamodikoe ^g   Mbelle, Nontombi ^l   Marais, Ben ^m   McIlleron, Helen ⁿ   McNeeley, David F ^o   Mendel, Carl ^h   Murray, Stephen ^h   Navarro, Eileen ^p   Anyalechi, E Gloria ^q   Porcalla, Ariel R ^p   Powell, Clydette ^r   Powell, Mair ^e   Rigaud, Mona ^s   Rouzier, Vanessa ^t   Samson, Pearl ^u   Schaaf, H Simon ⁱ   Shah, Seema ^v   Starke, Jeff ^w   Swaminathan, Soumya ^x   Wobudeya, Eric ^y   Worrell, Carol ^z   more..

^a STONY BROOK UNIVERSITY   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c THE INDUS HOSPITAL   (Pakistan)

^d HARVARD MEDICAL SCHOOL   (United States)

^e EUROPEAN MEDICINES AGENCY   (United Kingdom)

^f MÉDECINS SANS FRONTIÈRES   (Switzerland)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h TB Alliance   (United States)

ⁱ STELLENBOSCH UNIVERSITY   (South Africa)

^j UNIVERSITY OF THE PHILIPPINES   (Philippines)

^k Treatment Action Group   (United States)

^l UNIVERSITY OF PRETORIA   (South Africa)

^m University of Sydney   (Australia)

ⁿ UNIVERSITY OF CAPE TOWN   (South Africa)

^o NOVARTIS PHARMA AG   (Switzerland)

^p CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^q CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^r UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^s NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

^u CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^v NATIONAL INSTITUTES OF HEALTH   (United States)

^w BAYLOR COLLEGE OF MEDICINE   (United States)

^x NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^y MAKERERE UNIVERSITY   (Uganda)

^z EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

CHILDHOOD DISEASE; CLINICAL TRIAL (TOPIC); CONSENSUS; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; HUMAN; LONG TERM CARE; MEDICAL ETHICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STUDY DESIGN; TUBERCULOSIS; VULNERABLE POPULATION; ADOLESCENT; ADULT; AGE; CHILD; FEMALE; INFANT; MALE; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGE FACTORS; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CONSENSUS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; TUBERCULOSIS;

EID: 84929511425     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00007-9     Document Type: Review

References (82)

1. Global tuberculosis report 2013 2013, World Health Organization, WHO, Geneva, (accessed Nov 20, 2013). http://www.who.int/tb/publications/global_report/en/index.html.
2. Marais BJ, Graham SM, Maeurer M, Zumla A Progress and challenges in childhood tuberculosis. Lancet Infect Dis 2013, 13:287-289.
3. Perez-Velez CM, Marais BJ Tuberculosis in children. N Engl J Med 2012, 367:348-361.
4. Marais BJ, Graham SM, Cotton MF, Beyers N Diagnostic and management challenges for childhood tuberculosis in the era of HIV. J Infect Dis 2007, 196(suppl 1):S76-S85.
5. Marais BJ, Rabie H, Cotton MF TB and HIV in children-advances in prevention and management. Paediatr Respir Rev 2011, 12:39-45.
6. Hesseling AC, Cotton MF, Jennings T, et al. High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. Clin Infect Dis 2009, 48:108-114.
7. Dangor Z, Izu A, Hillier K, et al. Impact of the antiretroviral treatment program on the burden of hospitalization for culture-confirmed tuberculosis in South African children: a time-series analysis. Pediatr Infect Dis J 2013, 32:972-977.
8. Martinson NA, Moultrie H, van Niekerk R, et al. HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. Int J Tuberc Lung Dis 2009, 13:862-867.
9. Pensi T, Hemal A, Banerjee T Simultaneous HAART improves survival in children coinfected with HIV and TB. Trop Med Int Health 2012, 17:52-58.
10. Russell GK, Merle CS, Cooke GS, Casas EC, Silveira da Fonseca M, du Cros P Towards the WHO target of zero childhood tuberculosis deaths: an analysis of mortality in 13 locations in Africa and Asia. Int J Tuberc Lung Dis 2013, 17:1518-1523.
11. Dramowski A, Morsheimer MM, Jordaan AM, Victor TC, Donald PR, Schaaf HS Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa. Int J Tuberc Lung Dis 2012, 16:76-81.
12. Harrington M, McKenna L The Sentinel project for paediatric drug-resistant tuberculosis and treatment Action Group. "we can heal": prevention, diagnosis, treatment, care, and support: addressing drug-resistant tuberculosis in children (accessed April 20, 2015). http://www.tbcoalition.eu/2013/04/04/we-can-heal-drug-resistant-tuberculosis-in-children.
13. Mukinda FK, Theron D, van der Spuy GD, et al. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. Int J Tuberc Lung Dis 2012, 16:196-202.
14. Schaaf HS, Moll AP, Dheda K Multidrug- and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children. Clin Chest Med 2009, 30:667-683.
15. Schaaf HS, Marais BJ, Hesseling AC, Brittle W, Donald PR Surveillance of antituberculosis drug resistance among children from the Western Cape Province of South Africa-an upward trend. Am J Public Health 2009, 99:1486-1490.
16. Zignol M, Sismanidis C, Falzon D, Glaziou P, Dara M, Floyd K Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J 2013, 42:701-707.
17. Gegia M, Jenkins HE, Kalandadze I, Furin J Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009-2011. Int J Tuberc Lung Dis 2013, 17:624-629.
18. Seddon JA, Hesseling AC, Marais BJ, et al. Paediatric use of second-line anti-tuberculosis agents: a review. Tuberculosis (Edinb) 2012, 92:9-17.
19. Seddon JA, Thee S, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS Hearing loss in children treated for multidrug-resistant tuberculosis. J Infect 2013, 66:320-329.
20. Dooley KE, Mitnick CD, Ann DeGroote M, et al. Old drugs, new purpose: retooling existing drugs for optimised treatment of resistant tuberculosis. Clin Infect Dis 2012, 55:572-581.
21. Singh V, Kaur S Multi-drug resistant childhood tuberculosis. Indian J Pediatr 2011, 78:456-463.
22. Thee S, Zollner EW, Willemse M, Hesseling AC, Magdorf K, Schaaf HS Abnormal thyroid function tests in children on ethionamide treatment. Int J TubercLung Dis 2011, 15:1191-1193.
23. Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012, 186:953-964. the Sentinel Project on Pediatric Drug-Resistant Tuberculosis.
24. Tuberculosis medicines technology and market landscape September 2013, UNITAID, UNITAID, (accessed Nov 29, 2013). http://www.unitaid.org/images/marketdynamics/publications/UNITAID-TB_Medicines_Landscape-1st_edition.pdf, 1st edition.
25. Donald PR, Ahmed A, Burman WJ, et al. Requirements for the clinical evaluation of new anti-tuberculosis agents in children. Int J Tuberc Lung Dis 2013, 17:794-799.
26. Burman WJ, Cotton MF, Gibb DM, Walker AS, Vernon AA, Donald PR Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens. PLoS Med 2008, 5:e176.
27. Zumla A, Nahid P, Cole ST Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013, 12:388-404.
28. The global TB drug pipeline Working Group on New TB Drugs, (accessed Nov 20, 2013). http://www.newtbdrugs.org/pipeline.php.
29. The Global TB Drug Pipeline Drugs Working Group on new TB drugs, (accessed Nov 20, 2013). http://www.tballiance.org/downloads/Pipeline/TBAPipeline-Q3-2013.pdf.
30. Villemagne B, Crauste C, Flipo M, Baulard AR, Déprez B, Willand N Tuberculosis: the drug development pipeline at a glance. Eur J Med Chem 2012, 51:1-16.
31. Provisional CDC guidelines for the use and safety monitoring ofbedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep 2013, 62:1-12. Centres for Disease Control and Prevention.
32. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance 2013, WHO, World Health Organization, Geneva.
33. European Medicines Agency recommends two new treatment options for tuberculosis European Medicines Agency, (accessed Nov 24, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/11/WC500155472.pdf.
34. TB Drug Pipeline Global Alliance for TB Drug Development, (accessed Jan 27, 2015). http://www.tballiance.org/downloads/Pipeline/TBA%20Pipeline%20Q1%202015(2).pdf.
35. Nunn AJ, Rusen ID, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 2014, 15:353.
36. Lessem E, Jiménez-Levi E Funding for pediatric TB research, 2012. Supplement to the 2013 report on tuberculosis research funding trends, 2005-2012. h (accessed Dec 5, 2013). http://www.treatmentactiongroup.org/sites/tagone.drupalgardens.com/files/201310/TB_2013_TB_PEDS.pdf.
37. Roadmap for childhood tuberculosis, towards zero deaths 2013, WHO, World Health Organization, Geneva, (accessed Dec 5, 2013). http://apps.who.int/iris/bitstream/10665/89506/1/9789241506137_eng.pdf.
38. Guzman JD, Montes-Ricón X, Ribón W Research and development of new drugs against tuberculosis. Tuberculosis-current issues in diagnosis and management 2013, InTech, Rijeka. B.H. Mahboub, G.V. Mayank (Eds.).
39. Chan TE The search for minimal risk in international paediatric clinical trials. Santa Clara J Int Law 2006, 5:8-33.
40. WMA declaration of Helsinki-ethical principles for medical research involving human subjects World Medical Association, (accessed Nov 20, 2013). http://www.wma.net/en/30publications/10policies/b3/index.html.pdf?print-media-type&footer-right=page/toPage.
41. Macrae DJ The Council for International Organizations and Medical Sciences (CIOMS) guidelines on ethics of clinical trials. Proc Am Thorac Soc 2007, 4:176-178.
42. Gill D Ethical principles and operational guidelines for good clinical practice in paediatric research. Recommendations of the Ethics Working Group of the Confederation of European Specialists in Paediatrics (CESP). Eur J Pediatr 2004, 163:53-57. the Ethics Working Group of the Confederation of European Specialists in Paediatrics.
43. International ethical guidelines for biomedical research involving human subjects Council for International Organizations and Medical Sciences, the World Health Organizationthe World Health Organization, (accessed Nov 20, 2013). http://www.cioms.ch/publications/layout_guide2002.pdf.
44. Seddon JA, Visser DH, Bartens M, et al. Impact of drug resistance on clinical outcome in children with tuberculous meningitis. Pediatr Infect Dis J 2012, 31:711-716.
45. Title 4-pediatric research equity act of 2007 Food and Drug Administration, (accessed March 13, 2014). http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049870.pdf.
46. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use European Commission, (accessed April 30, 2014). http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf.
47. Food and Drug Administration Orphan drug regulations final rule (accessed Nov 20, 2013). http://www.gpo.gov/fdsys/pkg/FR-2013-06-12/pdf/2013-13930.pdf.
48. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products European Commission, (accessed Nov 20, 2013). http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf.
49. National Health Act 2004, Republic of South Africa (accessed Nov 20, 2013). http://www.info.gov.za/view/DownloadFileAction?id=68039.
50. Brigden G, Nyang'wa B-T, Cros Pd, et al. Principles for designing future regimens for multi drug-resistant tuberculosis. Bull World Health Organ 2014, 92:68-74.
51. Paccaly A, Petersen C, Patil S. Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in health subjects. 19th International AIDS Conference; Washington, DC, USA; July 22-27, 2012. 1255.
52. Peterson C, Paccaly A, Kim J. Delamanid, a new drug for multi-drug resistant tuberculosis (MDR-TB), and efavirenz do not show clinically relevant drug interactions in healthy subjects. 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy; San Franscisco, CA, USA; Sept 9-12, 2012. WEPE043.
53. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011, 365:2155-2166.
54. Drug safety communication. Fluoroquinolone antibacterial drugs: drug safety communication-risk for possibly permanent nerve damage Food and Drug Administration, (accessed Nov 24, 2013). http://www.fda.gov/downloads/Drugs/DrugSafety/UCM365078.pdf.
55. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366:2151-2160.
56. Kjöllerström P, Brito MJ, Gouveia C, Ferreira G, Varandas L Linezolid in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis in paediatric patients: experience of a paediatric infectious diseases unit. Scand J Infect Dis 2011, 43:556-559.
57. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012, 367:1508-1518.
58. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013, 41:1393-1400.
59. Dawson R, Diacon A PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert Opin Investig Drugs 2013, 22:927-932.
60. Drobac PC, Shin SS, Huamani P, et al. Risk factors for in-hospital mortality among children with tuberculosis: the 25-year experience in Peru. Pediatrics 2012, 130:e373-e379.
61. Vanden Driessche K, Persson A, Marais BJ, Fink PJ, Urdahl KB Immune vulnerability of infants to tuberculosis. Clin Dev Immunol 2013, 2013:781320.
62. Seddon JA, Hesseling AC, Finlayson H, et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis 2013, 57:1676-1684.
63. Seddon JA, Hesseling AC, Godfrey-Faussett P, Fielding K, Schaaf HS Risk factors for infection and disease in child contacts of multidrug-resistant tuberculosis: a cross-sectional study. BMC Infect Dis 2013, 13:392.
64. Chiappini E, Sollai S, Bonsignori F, Galli L, de Martino M Controversies in preventive therapy for children contacts of multidrug-resistant tuberculosis. J Chemother 2014, 26:1-12.
65. Seddon JA, Hesseling AC, Finlayson H, et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clinical Infect Dis 2013, 57:1676-1684.
66. Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother 2011, 55:5560-5567.
67. Chintu C Tuberculosis and human immunodeficiency virus co-infection in children: management challenges. Paediatr Respir Rev 2007, 8:142-147.
68. De Maayer T, Saloojee H Clinical outcomes of severe malnutrition in a high tuberculosis and HIV setting. Arch Dis Child 2011, 96:560-564.
69. Jaganath D, Mupere E Childhood tuberculosis and malnutrition. J Infect Dis 2012, 206:1809-1815.
70. Graham SM, Ahmed T, Amanullah F, et al. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis 2012, 205(suppl 2):S199-S208.
71. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis 2010, 10:803-812.
72. Seddon JA, Perez-Velez CM, Schaaf HS, et al. Consensus statement on research definitions for drug-resistant tuberculosis in children. J Pediatric Infect Dis Soc 2013, 2:100-109.
73. McNeeley DF, Raoof A, Lin J, Marais BJ The evaluation of new antituberculosis drugs in children. Antituberc Chemother 2011, 40:235-242.
74. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003, 349:1157-1167.
75. Guidance for industry: exposure-response relationships: study design, data analysis, and regulatory applications Food and Drug Administration, (accessed Nov 24, 2013). http://www.fda.gov.ezproxy.nihlibrary.nih.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072109.pdf.
76. Dunne J, Rodriguez WJ, Murphy MD, et al. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics 2011, 128:e1242-e1249.
77. Concept paper on extrapolation of efficacy and safety in medicine development European Medicine Agency, (accessed Nov 24, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/04/WC500142358.pdf.
78. Safeguarding children. Pediatric medical countermeasure research The Presidential Commission for the Study of Bioethical Issues, (accessed Dec 3, 2013). http://bioethics.gov/sites/default/files/PCSBI_Pediatric-MCM_2.pdf.
79. Halpern SD, Randolph AG, Angus DC No child left behind: enrolling children and adults simultaneously in critical care randomized trials. Crit Care Med 2009, 37:2638-2641.
80. Caldwell JC, Evans MV, Krishnan K Cutting edge PBPK models and analyses: providing the basis for future modeling efforts and bridges to emerging toxicology paradigms. J Toxicol 2012, 2012:852384.
81. Leeder JS, Kearns GL, Spielberg SP, van den Anker J Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol 2010, 50:1377-1387.
82. Jiménez-Levi EEJ-L Tuberculosis research and development: 2012 Report on tuberculosis research funding trends, 2005-2011 http://www.treatmentactiongroup.org/tbrd2012.